Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	17.47B -21.8%
Revenue (ttm)	4.22B -3.5%
Net Income	1.03B -9.3%
EPS	1.81 -8.6%
Shares Out	571.42M
PE Ratio	16.90
Forward PE	15.35
Dividend	1.31 (4.22%)
Ex-Dividend Date	Jun 1, 2026

Volume	2,355,520
Open	31.06
Previous Close	31.01
Day's Range	30.44 - 31.15
52-Week Range	30.49 - 42.75
Beta	0.06
Analysts	Buy
Price Target	39.42 (+28.91%)
Earnings Date	Aug 21, 2026

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,700
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2025, Autobio Diagnostics's revenue was 4.23 billion, a decrease of -5.47% compared to the previous year's 4.47 billion. Earnings were 1.07 billion, a decrease of -10.59%.